Radical cystectomy in the treatment of invasive bladder cancer. Long-term results in 1054 patients, J. Clin. Oncol, vol.19, pp.666-675, 2001. ,
Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder cancer Research Consortium, J. Urol, vol.176, pp.2414-2422, 2006. ,
American society of clinical oncology clinical practice guideline endorsement, J. Clin. Oncol, vol.34, pp.1945-1952, 2016. ,
Updated 2016 EAU Guidelines on muscle invasive and metastatic bladder cancer, Eur. Urol, vol.71, pp.462-475, 2017. ,
Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors, Eur. J. Canc, vol.42, pp.50-54, 2006. ,
Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin and cisplatin with pegfilgrastim support in muscle invasive urothelial cancer : pathologic, radiologic and biomarker correlates, J. Clin. Oncol, vol.32, pp.1882-1894, 2014. ,
Accelerated methotrexate, vinblastine, doxorubicin and cisplatin is safe, effective and efficient neoadjuvant treatment for muscle invasive bladder cancer. Results of a multicenter phase II study with molecular correlates of response and toxicity, J. Clin. Oncol, vol.32, pp.1895-1901, 2014. ,
BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer, Ann. Oncol, vol.22, pp.139-144, 2011. ,
Identification of distinct basal and luminal subtypes of muscle invasive bladder cancer with different sensitivities to front-line chemotherapy, Canc. Cell, vol.25, pp.152-165, 2014. ,
Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer, Eur. Urol, vol.68, pp.959-967, 2015. ,
Impact of molecular subtypes in muscleinvasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy, Eur. Urol, vol.72, pp.544-554, 2017. ,
, International Collaboration of Trialists, Neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle invasive bladder cancer. A randomised controlled trial, Lancet, vol.354, pp.533-540, 1999.
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advancer bladder cancer, N. Engl. J. Med, vol.349, pp.859-866, 2003. ,
Trends in use of perioperative chemotherapy for localized and locally advanced muscle invasive bladder cancer : a sign of changing tides, Eur. Urol, vol.67, pp.165-170, 2015. ,
Perioperative chemotherapy for bladder cancer in the general population : are practice patterns finally changing ?, Urol. Oncol, vol.36, 2018. ,
Refining the use of neoadjuvant chemotherapy in locally advanced bladder cancer : from conviction to optimization, Transl. Androl. Urol, vol.7, pp.757-759, 2018. ,
Neoadjuvant dose dense MVAC versus gemcitabine and cisplatin in patients with cT3-4a N0M0 bladder cancer treated with radical cystectomy, J. Urol, vol.199, pp.1452-1458, 2018. ,
Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy : a meta-analysis, Eur. Urol, vol.65, pp.350-357, 2014. ,
Outcomes following complete response to neo-adjuvant chemotherapy for muscle invasive urothelial carcinoma of the bladder in patients refusing radical cystectomy, Oncology, vol.11, pp.116-121, 2018. ,
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase II trial, Lancet, vol.387, pp.1909-1920, 2016. ,
Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N. Engl. J. Med, vol.376, pp.1015-1026, 2017. ,
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, vol.515, pp.558-562, 2014. ,